CIMG is a small, early-stage company that sells health and wellness products and AI-enabled computing hardware in Asia, primarily China. The company pivoted away from a specialty coffee business in mid-2024 and now operates three product lines. The Maca Series includes maca-based dietary supplements and functional foods marketed to Asian consumers as natural health products. The Homology of Medicine and Food Series covers products guided by traditional Chinese medicine principles, including Huomao-branded liquor and exosome eye drops. The Computing Power Series consists of GPU hardware devices embedded with AI data-processing modules, customized for industry-specific tasks and sold directly to enterprise customers like China Merchants Bank. CIMG's business model is primarily that of a distributor — sourcing or producing products and reselling them to wholesale distributors or enterprise customers at a markup. Revenue is heavily concentrated: two customers accounted for 96% of FY25 revenue, and a single one-time exosome eye drop order represented roughly 60% of total FY25 revenue, raising significant questions about revenue recurrence. CIMG's growth strategy includes expanding its retail footprint across Chinese convenience stores and vending machines, building online sales through platforms like JD.com and Alibaba, and pursuing M&A to broaden its product portfolio. CIMG is incorporated in Nevada and listed on Nasdaq under the ticker "IMG," though the company has faced ongoing Nasdaq compliance issues related to minimum stockholders' equity, bid price, and late filings.